Info
indications-of-autologous_stem_cell_transplantation
Multiple myeloma (MM)
Most common indication for ASCT. Generally palliative intent
Up-front consolidation following response to induction chemo or for relapsed/refractory dz (IFM 2009 trial, Blood 2020;136:39; EMN02/HO95 MM trial, Lancet Haematol 2020;7:e456)
Hodgkin lymphoma (HL)
Chemo-sensitive relapsed dz. Curative intent (Cochrane Database Syst Rev 2013;CD009411)
DLBCL
Chemo-sensitive relapsed dz. Curative intent (Parma Trial, NEJM 1995;333:1540; CORAL study, JCO 2010;28:4184)
CNS Lymphoma (DLBCL)
Chemo-sensitive relapsed dz or for up-front consolidation. Curative intent (Blood 2015;125:1403)
Follicular lymphoma (FL)
Chemo-sensitive early relapsed dz or dz that has progressed to clinically aggressive histology (eg, DLBCL) (JCO 2013;31:1164; LymphoCare Study, BBMT 2018;24:1163)
Peripheral T-cell lymphoma
Consolidation in first CR or for chemo-sensitive relapsed dz. Curative intent (Blood 2012;30:3093; JCO 2013;31:3100)
Mantle cell lymphoma
Consolidation in first CR or for chemo-sensitive relapsed dz (BJH 2012;158:355; Blood 2005;105:2677)
Ig light chain (AL) amyloidosis
Consolidation following initial response to chemo or for relapsed dz. Palliative intent (Blood 2015;126:2345)